Semiconductor Bolometers Give Background-Limited Performance

Semiconductor bolometers that are capable of detecting electromagnetic radiation over most or all of the infrared spectrum and that give background-limited performance at operating temperatures from 20 to 300 K have been invented. The term background-limited performance as applied to a bolometer, thermopile, or other infrared detector signifies that the ability to detect infrared signals that originate outside the detector is limited primarily by thermal noise attributable to the background radiation generated external to the bolometer. The signal-to-noise ratios and detectivities of the bolometers and thermopiles available prior to this invention have been lower than those needed for background-limited performance by factors of about 100 and 10, respectively. Like other electrically resistive bolometers, a device according to the invention exhibits an increase in electrical resistance when heated by infrared radiation. Depending on whether the device is operated under the customary constant- current or constant-voltage bias, the increase in electrical resistance can be measured in terms of an increase in voltage across the device or a decrease in current through the device, respectively. In the case of a semiconductor bolometer, it is necessary to filter out visible and shorter-wavelength light that could induce photoconductivity and thereby counteract all or part of the desired infrared- induced increase in resistance. The basic semiconductor material of a bolometer according to the invention is preferably silicon doped with one or more of a number of elements, each of which confers a different variable temperature coefficient of resistance. Suitable dopants include In, Ga, S, Se, Te, B, Al, As, P, and Sb. The concentration of dopant preferably lies in the range between 0.1 and 1,000 parts per billion

Resonant infrared detector with substantially unit quantum efficiency

A resonant infrared detector includes an infrared-active layer which has first and second parallel faces and which absorbs radiation of a given wavelength. The detector also includes a first tuned reflective layer, disposed opposite the first face of the infrared-active layer, which reflects a specific portion of the radiation incident thereon and allows a specific portion of the incident radiation at the given wavelength to reach the infrared-active layer. A second reflective layer, disposed opposite the second face of the infrared-active layer, reflects back into the infrared-active layer substantially all of the radiation at the given wavelength which passes through the infrared-active layer. The reflective layers have the effect of increasing the quantum efficiency of the infrared detector relative to the quantum efficiency of the infrared-active layer alone

Changes in Plasma Potassium During Graded Aerobic Exercise and Two Hours of Recovery

Plasma potassium increases with exercise intensity. Subjects (n=8) were monitored for changes in plasma potas-sium while exercising at progressively increasing steady-state intensities and for two hours of recovery. Plasma po-tassium was significantly increased at 100% of VO2peak compared to 20% and 40% (p<0.01). Plasma potassium at 60 and 120 minutes of recovery from exercise was significantly higher than 6 minutes post exercise (p<0.015). These results support the supposition that high-intensity exercise may lead to hyperkalemia, and also indicates that in-creases in [K + ] occur up to two hours after the cessation of exercise, a newly reported phenomenon. Although, high levels of plasma potassium are known to cause cardiac abnormalities and related events, exercise induced changes in normal healthy adults are not currently believed to have clinical implications

Basic Mechanisms of Arsenic Trioxide (ATO)-Induced Apoptosis in Human Leukemia (HL-60) Cells

<p>Abstract</p> <p>Background</p> <p>Acute promyelocytic leukemia (APL) is a blood cancer that affects people of all ages and strikes about 1,500 patients in the United States each year. The standard treatment of APL has been based on the combined administration of all-trans retinoic acid and chemotherapy including anthracyclins and cytarabine. However, 10-20% of patients relapse, with their disease becoming resistant to conventional treatment. Recently the Food and Drug Administration has approved the use of arsenic trioxide (ATO) or Trisenox for the treatment of APL, based on clinical studies showing a complete remission, especially in relapsed patients. In a recently published study we demonstrated that ATO pharmacology as an anti-cancer drug is associated with its cytotoxic and genotoxic effects in human leukemia cells.</p> <p>Methods</p> <p>In the present study, we further investigated the apoptotic mechanisms of ATO toxicity using the HL-60 cell line as a test model. Apoptosis was measured by flow cytometry analysis of phosphatidylserine externalization (Annexin V assay) and caspase 3 activity, and by DNA laddering assay.</p> <p>Results</p> <p>Flow cytometry data showed a strong dose-response relationship between ATO exposure and Annexin-V positive HL-60 cells. Similarly, a statistically significant and dose-dependent increase (<it>p <</it>0.05) was recorded with regard to caspase 3 activity in HL60 cells undergoing late apoptosis. These results were confirmed by data of DNA laddering assay showing a clear evidence of nucleosomal DNA fragmentation in ATO-treated cells.</p> <p>Conclusion</p> <p>Taken together, our research demonstrated that ATO represents an apoptosis-inducing agent and its apoptotic mechanisms involve phosphatidylserine externalization, caspase 3 activation and nucleosomal DNA fragmentation.</p

Exercise-Induced Glycogen Reduction Increases Muscle Activity

International Journal of Exercise Science 9(3): 336-346, 2016. Intramuscular glycogen stores are an important energy source during extended bouts of strenuous exercise. A substantial reduction in glycogen could influence neural muscular drive and result in a decreasing quality of exercise performance and potentially increased injury rates. The aim of this study was to examine the effect of glycogen reduction on motor drive as determined by the surface electromyogram (EMG) amplitude and median frequency during a cycling graded exercise test. Eight trained cyclists performed a discontinuous cycling graded exercise test to exhaustion under both normal and glycogen reduced conditions. EMG was collected from the vastus lateralis. Repeated measures regression models indicated that EMG amplitudes were elevated at cycling workloads higher than 196 Watts and metabolic workloads higher than 40.8 ml/kg/min, corresponding to 77% VO2max. There was no effect of increases in workload or glycogen reduction on EMG median frequency. Changes in mechanical and metabolic workload had a substantial effect on EMG amplitude (Cohen’s f2 = 0.227 and 0.247, respectively), but not median frequency (Cohen’s f2 = 0.026 and 0.033, respectively). Thus, EMG amplitude is a more effective and reliable measure to examine changes in motor drive during variable workload conditions and metabolic perturbations. The results suggest that healthy glycogen reduced humans require higher levels of muscle activity in order to attain a given mechanical and metabolic workload. This may affect the long term performance of professional and military athletes who need to be able to perform at a high level for extended periods of activity

Actical Accelerometry Cut-points for Quantifying Levels of Exertion: Comparing Normal and Overweight Adults

Int J Exerc Sci 5(2) : 170-182, 2012. Weight, body fatness and ambulatory pattern all have the potential to affect accelerometer output and cause differences in output between overweight and normal-weight adults. The purpose of this study was to determine if Actical (Philips Respironics, Bend, OR) activity count cut-points for moderate and vigorous intensity exercise are different for overweight adults compared to normal-weight adults. Overweight adults with BMI \u3e25 kg/m² (n=29) and Normal-Weight adults (n=25) walked at 3.2 and 4.8 km∙h-1 and ran at 6.4 km∙h-1 on a treadmill while simultaneously wearing an Actical accelerometer and obtaining measurements of oxygen uptake. Counts per minute (counts∙min-1) were determined at 3 METS (moderate) and 6 METS (vigorous) using ROC curves. The counts∙min-1 at 3 METs was 1726 and 1923 counts∙min-1 for Overweight and Normal-Weight groups, respectively. The cut-points at 6 METs were 4117 and 4032 counts∙min-1 for Overweight and Normal-Weight groups, respectively. The differences between groups were not statistically significant (p\u3e0.73 for both). Correlations between BMI and counts∙min-1 were not significant (p\u3e0.05) at any speed for the Normal-Weight group but were significant at 3.2 and 4.8 km∙h-1 for the Overweight group. Although there appears to be some relationship between activity counts∙min-1 and BMI, the results suggest that similar cut-points may be used for normal weight and overweight adults. However, the greater variability in counts at each speed and lower ROC curve areas for overweight adults suggest that it is harder to classify the activity intensity of overweight subjects compared to normal weight subjects

Toxic Absence: Why Leader Presence Matters in Times of Crisis

Aims. This study examines the importance of senior-leader presence on the “frontline” in times of crisis. Background. The COVID-19 pandemic placed unprecedented demands on nurses charged with delivering critical care. Extant research suggests that the active presence of ward-level leaders has an important role to play in supporting frontline staff and mediating the negative impacts of stress and burnout. There is little evidence on the impact of senior leader presence or absence on the experience of frontline critical care nurses, particularly at times of crisis. Methods. A three-phase qualitative interview study of critical care nurses in the UK and Ireland. A total of 107 semistructured interviews with 54 nurses representing 38 different healthcare units. Results. Senior-leader presence at the time of crisis serves as an important symbol of organisational support. Where senior leaders are not meaningfully present, they risk allowing the necessary pain of difficult work situations to become toxic. Toxicity is manifested with increased staff stress, emotional ills, absence, and turnover. Conclusions. Senior leaders must balance their responsibilities for strategy and structures with the frontline presence required to shape a positive emotional climate. Implications for Nursing Management. Senior managers should consider supplementing their strategic focus with punctuated returns to the floor. Symbolically, leaders who get their hands dirty embody a sense of mutual struggle and practical support. Managerially, time on the floor increases the opportunities for collecting primary data to improve decision-making and support

Multi-Line Gamma-Ray Spectrometer Performance of a Si(Li) Detector Stack

Experimental data is presented which for the first time displays multi-line spectrometer performance of a Si(Li) detector stack at elevated temperature. The stack consists of four elements, each with a 2 cm diameter active area. Ba-133 and Ag-110m spectra are obtained using various techniques to enhance the peak-to-background ratio. Spectral data are shown as a function of temperature (94 K less than or = T less than or = 230 K) using optimized peak shaping

Results of a reevaluation of cardiovascular outcomes in the RECORD trial

Background The US Food and Drug Administration (FDA) required a reevaluation of cardiovascular (CV) outcomes in the RECORD trial. This provided an opportunity to assess the implications of event adjudication by 2 groups and quantify the differences as well as to use new FDA end point definitions in development.&lt;p&gt;&lt;/p&gt; Methods Original data were used to systematically identify all potential deaths, myocardial infarctions (MIs), and strokes. Site investigators were approached for additional source documents and information about participants lost to follow-up. Suspected events were adjudicated using standard procedures, and the results were compared with the original trial outcomes.&lt;p&gt;&lt;/p&gt; Results Follow-up for mortality was 25,833 person-years, including an additional 328 person-years identified during the reevaluation effort. A total of 184 CV or unknown-cause deaths (88 rosiglitazone, 96 metformin/sulfonylurea), 128 participants with an MI (68 rosiglitazone, 60 metformin/sulfonylurea), and 113 participants with a stroke (50 rosiglitazone, 63 metformin/sulfonylurea) were included. The hazard ratio (HR) for rosiglitazone versus metformin/sulfonylurea for the end point of CV (or unknown cause) death, MI, or stroke was 0.95 (95% CI 0.78-1.17) compared with 0.93 (95% CI 0.74-1.15) for the original RECORD results. Treatment comparisons for MI (HR 1.13, 95% CI 0.80-1.59) and mortality (HR 0.86, 95% CI 0.68-1.08) were also the same compared with the original RECORD results. Sensitivity analyses were also consistent with the original RECORD results. Analyses using the FDA definitions showed similar results.&lt;p&gt;&lt;/p&gt; Conclusions Only a modest number of additional person-years of follow-up were ascertained from this reevaluation of CV end points in RECORD. Observed HRs and CIs from these analyses using the original RECORD or new FDA end point definitions showed similar treatment effects of rosiglitazone compared with the original RECORD results.&lt;p&gt;&lt;/p&gt